

INBORN ERRORS OF TYPE I IFN IMMUNITY IN PATIENTS WITH LIFE-THREATENING COVID-19

Qian Zhang¹, Paul Bastard^{2,3}, Zhiyong Liu¹, Jérémie Le Pen⁴, Marcela Moncada-Velez¹, Jie Chen¹,
Masato Ogishi¹ et al.

¹*St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA*

²*Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France*

³*University of Paris, Imagine Institute, Paris, France*

⁴*Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA*

Clinical outcome upon infection with SARS-CoV-2 ranges from silent infection to lethal COVID-19. We have found an enrichment in rare variants predicted to be loss-of-function (LOF) at the 13 human loci known to govern TLR3- and IRF7-dependent type I interferon (IFN) immunity to influenza virus, in 659 patients with life-threatening COVID-19 pneumonia, relative to 534 subjects with asymptomatic or benign infection. By testing these and other rare variants at these 13 loci, we experimentally define LOF variants in 23 patients (3.5%), aged 17 to 77 years, underlying autosomal recessive or dominant deficiencies. We show that human fibroblasts with mutations affecting this pathway are vulnerable to SARS-CoV-2. Inborn errors of TLR3- and IRF7-dependent type I IFN immunity can underlie life-threatening COVID-19 pneumonia in patients with no prior severe infection.